Docetaxel-resistant prostate cancer cells remain sensitive to S-trityl-L-cysteine-mediated Eg5 inhibition

Molecular Cancer Therapeutics

Volumn 9, Issue 6, 2010, Pages 1730-1739

  Wiltshire, Carolyn ^a,b   Singh, Babloo L ^a,b   Stockley, Jacqueline ^c   Fleming, Janis ^b   Doyle, Brendan ^b   Barnetson, Robert ^b   Robson, Craig N ^c   Kozielski, Frank ^b   Leung, Hing Y ^a,b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b NHS GREATER GLASGOW AND CLYDE   (United Kingdom)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE; DOCETAXEL; KINESIN 5; KINESIN EG5; TRITYL DERIVATIVE; TRITYLCYSTEINE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER RESISTANCE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL STRAIN LNCAP; CONTROLLED STUDY; DRUG MECHANISM; DRUG SENSITIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; MITOSIS INHIBITION; POLYPLOIDY; PRIORITY JOURNAL; PROSTATE CANCER;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CYSTEINE; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; KINESIN; MALE; P-GLYCOPROTEIN; PROPIDIUM; PROSTATIC NEOPLASMS; TAXOIDS; UP-REGULATION;

EID: 77953399826     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-09-1103     Document Type: Article

References (26)

1. Hirokawa N, Noda Y. Intracellular transport and kinesin superfamily proteins, KIFs: structure, function, and dynamics. Physiol Rev 2008;88:1089-118.
2. Zhu C, Zhao J, Bibikova M, et al. Functional analysis of human microtubule-based motor proteins, the kinesins and dyneins, in mitosis/cytokinesis using RNA interference. Mol Biol Cell 2005;16:3187-99. (Pubitemid 40962591)
3. Blangy A, Lane HA, d'Herin P, Harper M, Kress M, Nigg EA. Phosphorylation by p34cdc2 regulates spindle association of human Eg5, a kinesin-related motor essential for bipolar spindle formation in vivo. Cell 1995;83:1159-69.
4. Mayer TU, Kapoor TM, Haggarty SJ, King RW, Schreiber SL, Mitchison TJ. Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. Science 1999;286:971-4.
5. Bergnes G, Brejc K, Belmont L. Mitotic kinesins: prospects for antimitotic drug discovery. Curr Top Med Chem 2005;5:127-45. (Pubitemid 40514510)
6. DeBonis S, Skoufias DA, Lebeau L, et al. In vitro screening for inhibitors of the human mitotic kinesin Eg5 with antimitotic and antitumor activities. Mol Cancer Ther 2004;3:1079-90.
7. Skoufias DA, DeBonis S, Saoudi Y, et al. S-Trityl-L-cysteine is a reversible, tight binding inhibitor of the human kinesin Eg5 that specifically blocks mitotic progression. J Biol Chem 2006;281:17559-69. (Pubitemid 44035555)
8. Kozielski F, Skoufias DA, Indorato RL, et al. Proteome analysis of apoptosis signaling by S-trityl-L-cysteine, a potent reversible inhibitor of human mitotic kinesin Eg5. Proteomics 2008;8:289-300. (Pubitemid 351212328)
9. Ogo N, Oishi S, Matsuno K, Sawada J, Fujii N, Asai A. Synthesis and biological evaluation of L-cysteine derivatives as mitotic kinesin Eg5 inhibitors. Bioorg Med Chem Lett 2007;17:3921-4. (Pubitemid 46920939)
10. Debonis S, Skoufias DA, Indorato RL, et al. Structure-activity relationship of S-trityl-L-cysteine analogues as inhibitors of the human mitotic kinesin Eg5. J Med Chem 2008;51:1115-25.
11. Figg WD, Walls RG, Cooper MR, et al. In vitro antitumor effect of hydroxyurea on hormone-refractory prostate cancer cells and its potentiation by phenylbutyrate. Anticancer Drugs 1994;5:336-42.
12. McCracken SR, Ramsay A, Heer R, et al. Aberrant expression of extracellular signal-regulated kinase 5 in human prostate cancer. Oncogene 2008;27:2978-88. (Pubitemid 351668010)
13. Lee JS, Paull K, Alvarez M, et al. Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen. Mol Pharmacol 1994;46:627-38. (Pubitemid 24334752)
14. Lanzi C, Cassinelli G, Cuccuru G, et al. Cell cycle checkpoint efficiency and cellular response to paclitaxel in prostate cancer cells. Prostate 2001;48:254-64. (Pubitemid 32816551)
15. Carroll AG, Voeller HJ, Sugars L, Gelmann EP. p53 oncogene mutations in three human prostate cancer cell lines. Prostate 1993;23:123-34. (Pubitemid 23289894)
16. Lanni JS, Jacks T. Characterization of the p53-dependent postmitotic checkpoint following spindle disruption. Mol Cell Biol 1998;18:1055-64.
17. Tsuiki H, Nitta M, Tada M, Inagaki M, Ushio Y, Saya H. Mechanism of hyperploid cell formation induced by microtubule inhibiting drug in glioma cell lines. Oncogene 2001;20:420-9.
18. Shi J, Orth JD, Mitchison T. Cell type variation in responses to antimitotic drugs that target microtubules and kinesin-5. Cancer Res 2008;68:3269-76.
19. Gascoigne KE, Taylor SS. Cancer cells display profound intra- and interline variation following prolonged exposure to antimitotic drugs. Cancer Cell 2008;14:111-22.
20. Lo Nigro C, Maffi M, Fischel JL, Formento P, Milano G, Merlano M. The combination of docetaxel and the somatostatin analogue lanreotide on androgen-independent docetaxel-resistant prostate cancer: experimental data. BJU Int 2008;102:622-7.
21. Hayashi N, Koller E, Fazli L, Gleave ME. Effects of Eg5 knockdown on human prostate cancer xenograft growth and chemosensitivity. Prostate 2008;68:1283-95.
22. Huszar D, Theoclitou ME, Skolnik J, Herbst R. Kinesin motor proteins as targets for cancer therapy. Cancer Metastasis Rev 2009;28:197-208.
23. Beer TM, Goldman B, Synold TW, et al. Southwest Oncology Group phase II study of ispinesib in androgen-independent prostate cancer previously treated with taxanes. Clin Genitourin Cancer 2008;6:103-9.
24. Rello-Varona S, Vitale I, Kepp O, et al. Preferential killing of tetraploid tumor cells by targeting the mitotic kinesin Eg5. Cell Cycle 2009;8:1030-5.
25. Tao W, South VJ, Zhang Y, et al. Induction of apoptosis by an inhibitor of the mitotic kinesin KSP requires both activation of the spindle assembly checkpoint and mitotic slippage. Cancer Cell 2005;8:49-59.
26. Marcus AI, Peters U, Thomas SL, et al. Mitotic kinesin inhibitors induce mitotic arrest and cell death in Taxol-resistant and -sensitive cancer cells. J Biol Chem 2005;280:11569-77.